Azitra (AZTR) Q2 2025 earnings summary

Executive summary

• Focused on developing precision dermatology therapies using engineered proteins and live biotherapeutics, with three lead programs in clinical and preclinical stages.

• Achieved 50% enrollment and initial safety results in Phase 1b trial for ATR-12 in Netherton syndrome, showing a promising safety profile.

• Presented Phase 1/2 trial design for ATR-04 in EGFR inhibitor-associated rash at ASCO 2025; first patient dosing expected in Q3 2025.

• Initial clinical safety results for ATR-12 (Netherton syndrome) reported in H1 2025; ATR-04 (EGFRi rash) to begin Phase 1/2 dosing in Q3 2025.

• No commercial revenue; operations funded by equity offerings and an equity line of credit.

Financial highlights

• Net loss for Q2 2025 was $2.9 million, a 10% increase year-over-year; six-month net loss was $5.96 million, up 7%.

• R&D expenses were $1.4 million for Q2 2025, up from $1.1 million in Q2 2024; G&A expenses remained flat at $1.5 million.

• Total assets as of June 30, 2025 were $4.0 million, with $1.0 million in cash and cash equivalents.

• Working capital at quarter-end was $0.3 million.

• Cash used in operations for the first half of 2025 was $5.9 million; net cash from financing activities was $2.4 million.

Outlook and guidance

• Cash on hand is not sufficient to fund operations for the next twelve months; additional capital will be required.

• Management plans to seek further equity or debt financing and may consider alternative business strategies if funding is not secured.

• First patient dosing for ATR-04 Phase 1/2 trial expected in Q3 2025.

• Topline data for ATR-12 Phase 1b trial anticipated in Q1 2026.

• Remainder of 2025 expected to be milestone-rich with key clinical updates.